1173003-00-3

Basic information

• Product Name: N-(3-diethylamino-propyl)-3-[3-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide
• Synonyms: N-(3-diethylamino-propyl)-3-[3-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide
• CAS NO: 1173003-00-3
• Molecular Weight: 428.577
• Mol File: 1173003-00-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(3-diethylamino-propyl)-3-[3-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-diethylamino-propyl)-3-[3-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide(1173003-00-3)
• EPA Substance Registry System: N-(3-diethylamino-propyl)-3-[3-((E)-2-pyridin-4-yl-vinyl)-phenylamino]-benzamide(1173003-00-3)

Safety Data

• Hazardous Substances Data: 1173003-00-3(Hazardous Substances Data)

Upstream product

• 46837-95-0 4-[2-(3-nitrophenyl)ethenyl]pyridine 
• 100-43-6 4-vinylpyridine 
• 1711-09-7 3-bromobenzoyl chloride 
• 585-79-5 m-nitrobromobenzene 
• 104-78-9 diethylaminopropylamine 
• 349405-27-2 3-bromo-N-(3-diethylamino-propyl)benzamide 
• 32598-04-2 (E)-3-(2-(pyridin-4-yl)vinyl)aniline 

Relevant articles and documents

Compounds for use as therapeutic agents affecting p53 expression and/or activity

The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a -NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a -CONR7R8 group, a -SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a -(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a -(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use as an agent for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.